Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 3/20 | 0.40 |
| ▸ | GRM5 | P41594 | 3/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.39 |
| ▸ | PRF1 | P14222 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3639851 | 0.95 | GRM1 (0.44) | ADAM17GRM5GRM1PRF1KDM4E | |
| SCHEMBL3637586 | 0.91 | GRM1 (0.42) | ADAM17GRM5GRM1KDM4EALDH1A1 | |
| SCHEMBL3632640 | 0.91 | ADAM17 (0.43) | ADAM17GRM5GRM1PRF1MAOA | |
| SCHEMBL3640741 | 0.90 | ADAM17 (0.41) | ADAM17GRM5GRM1PRF1KDM4E | |
| SCHEMBL3633480 | 0.90 | DRD2 (0.40) | ADAM17GRM5GRM1PRF1HRH3 | |
| SCHEMBL3635276 | 0.90 | PRF1 (0.37) | ADAM17GRM5GRM1PRF1MAOA | |
| SCHEMBL3637081 | 0.89 | ADAM17 (0.39) | ADAM17GRM5GRM1KDM4EALDH1A1 | |
| SCHEMBL3639581 | 0.87 | ADAM17 (0.40) | ADAM17KDM4EALDH1A1HRH3MAOA | |
| SCHEMBL3635212 | 0.85 | PRF1 (0.40) | ADAM17GRM5GRM1PRF1KDM4E | |
| SCHEMBL3639893 | 0.85 | PRF1 (0.40) | ADAM17GRM5GRM1PRF1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242933-B2 | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-26 | — | — | US | claimed |
| EP-2167464-B1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) | ABBVIE DEUTSCHLAND (DE) | 2014-12-03 | — | — | EP | claimed |
| US-9242933-B2 | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-26 | — | — | US | disclosed |
| EP-2167464-B1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) | ABBVIE DEUTSCHLAND (DE) | 2014-12-03 | — | — | EP | disclosed |
| EP-2167464-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) | Abbott GmbH & Co. KG (DE) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008145616-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) | ABBOTT GMBH & CO. KG (DE) | 2008-12-04 | — | — | WO | disclosed |
| US-20080300260-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300260-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) | GRM2, GRIN2C, GRM1 | ADAM17 4441/4885GRM5 5/4885GRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.